Our findings build on this emerging evidence and suggest that PTGFRN may serve as a pan‐cancer marker of EVs derived through non‐canonical, ESCRT‐independent pathways—distinct from the classical CD9‐, CD63‐, or CD81‐marked small EVs. Here, CD9 is linked to cancer.